Skip to main content

Table 2 Patients characteristics

From: Feasibility of constant dose rate VMAT in the treatment of nasopharyngeal cancer patients

Patients no. Staging Gender Age PTC-CTV volume (cm3) PTV-GTV volume (cm3)
1 T2N2MX M 48 618.0 59.6
2 T2N1MX M 63 757.7 85.5
3 T3N0M0 M 71 589.1 62.2
4 T4N0MX M 59 546.8 171.0
5 T3N3MX M 71 504.2 92.4
6 T2N2MX F 66 416.5 64.4
7 T4N0MX M 55 739.7 83.4
8 T2N2MX M 39 498.1 45.3
9 T2N3MX M 48 462.4 45.8
10 T1N1M0 M 62 603.8 93.1
11 T2bN1M0 F 55 725.6 89.7
12 T2bN2M0 F 65 668.0 92.8